Core Viewpoint - The Hong Kong pharmaceutical sector is experiencing significant growth, particularly in innovative drugs, with many companies seeing their stock prices double [1]. Group 1: Market Dynamics - The listing of TIDE Pharmaceutical (03880.HK) on June 30 attracted considerable market attention, with a subscription rate of 301.15 times for public offerings and 2.43 times for international offerings [2]. - TIDE Pharmaceutical is positioned in a favorable market window, driven by two core market dynamics: the global capital market's shift towards Chinese technology assets and the upcoming results in China's innovative drug industry by 2025 [3][4]. Group 2: Industry Growth Potential - The global peptide drug market is projected to reach $261.2 billion by 2032, with a compound annual growth rate (CAGR) of 12.6% [7]. - In China, the GLP-1 drug market is expected to grow from $100 million in 2018 to $1.3 billion in 2023, with a CAGR of 65.3%, and further to $23.2 billion by 2032, with a CAGR of 37.3% [11]. - TIDE Pharmaceutical is strategically focusing on the GLP-1 sector, which is becoming a major trend in the pharmaceutical industry [7]. Group 3: Competitive Positioning - TIDE Pharmaceutical is recognized as the third-largest peptide CRDMO globally, with nine GLP-1 molecule development projects and partnerships with seven clients [15]. - The company is expanding its production capacity, with facilities in Hangzhou and the U.S., to meet the anticipated surge in market demand [16]. Group 4: Technological Advancements - TIDE Pharmaceutical has over 20 years of experience in the peptide CRDMO industry, with a strong team of experts and a wealth of knowledge in peptide drug design and synthesis [18]. - The company utilizes multiple proprietary technology platforms, including OmniPeptSynth™ and PeptiNuclide LinkTech™, to enhance its innovation capabilities [19][20]. - TIDE's long-term service capabilities have earned recognition from pharmaceutical companies, further solidifying its position in the peptide drug sector [21]. Group 5: Future Outlook - TIDE Pharmaceutical is well-positioned to benefit from the upcoming expiration of patents for major GLP-1 drugs, which will create significant demand for generic APIs [23]. - The company is also exploring opportunities in the oligonucleotide drug sector, indicating a broad market potential [23]. - Overall, TIDE Pharmaceutical's strategic positioning and technological expertise suggest strong long-term growth potential in the innovative drug market [22].

以"飞地经济"为导向，沪苏合作产业园区正在从产业链提升角度推进长三角一体化向纵深发展。 5月30日，在2025年度长三角主要领导座谈会举办前夕，第一财经走访了沪苏合作共建的多个产业园 区。据沪苏大丰公司产业发展促进中心副总监李力巍的介绍，作为上海与江苏共建的省际合作园区，沪 苏大丰产业联动聚集区（下称"聚集区"）现已开发4平方公里，跨域交通是该聚集区的一大核心优势， 由于聚集区位于大丰城区与港区之间，东连大丰港区、西通城区，距大丰高铁站车程25分，已全面融入 了上海'一小时经济圈'。" 比如，顶层规划上，沪苏两地根据《大丰区国土空间分区规划》等文件来开展产业、交通、民生等20多 个专项领域的协同工作；基础设施上，大丰采取相关板块与市、区级投融资平台协同共建的模式，统筹 推进其他领域配套基础设施的建设。 再如，项目引领上，沪苏两地会共同招引一些重大项目，去年签约落户亿元以上的产业项目就有118 个，"以康养产业为例，大丰作为上海的后花园，不但有'米袋子''菜篮子''奶罐子'的功能，也能够承担 起上海域外农场康养基地的功能，近期针对这一类型的康养基地，我们做了重点规划。"此外，在科技 创新上，与南京大学共建的江苏 ...